SCHEMBL6286589

SCHEMBL6286589

N=C(N)c1cccc(NC(=O)C(=O)Nc2ccc(S(=O)(=O)NCc3ccccc3)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 5/20 0.53
TMPRSS6 Q8IU80 2/20 0.53
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
TSHR P16473 1/20 0.52
CYP2C19 P33261 1/20 0.52
KMT2A Q03164 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MAPT P10636 2/20 0.52
MEN1 O00255 1/20 0.52
NPC1 O15118 1/20 0.51
MITF O75030 1/20 0.51
MAPK1 P28482 1/20 0.51
RAB9A P51151 1/20 0.51
NAMPT P43490 2/20 0.50
PRMT1 Q99873 1/20 0.50
HTT P42858 2/20 0.49
LMNA P02545 2/20 0.49
PLAU P00749 1/20 0.49
HPN P05981 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6280117 0.94 MEN1 (0.60) F2TMPRSS6CYP2D6CYP2C9TSHR
SCHEMBL6285904 0.92 NAMPT (0.56) F2TMPRSS6KMT2ASMN1; SMN2MAPT
SCHEMBL6276427 0.90 GPR55 (0.56) F2TMPRSS6CYP2D6CYP2C9TSHR
SCHEMBL6276930 0.85 CA2 (0.53) TSHRKMT2ASMN1; SMN2MAPTMEN1
SCHEMBL6276432 0.82 CYP2D6 (0.47) F2TMPRSS6CYP2D6CYP2C9TSHR
SCHEMBL6280114 0.81 NAMPT (0.62) F2TMPRSS6KMT2ASMN1; SMN2MAPT
SCHEMBL4168948 0.80 KEAP1 (0.61) CYP2D6CYP2C9TSHRCYP2C19KMT2A
SCHEMBL8170686 0.80 KEAP1 (0.65) F2TMPRSS6SMN1; SMN2PRMT1LMNA
SCHEMBL6281156 0.79 TSHR (0.65) CYP2D6CYP2C9TSHRCYP2C19KMT2A
SCHEMBL12010884 0.77 NAMPT (0.72) CYP2D6CYP2C9TSHRCYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949567-B2 Compounds for the treatment of protozoal diseases 4SC AG (DE) 2005-09-27 US disclosed
EP-1395548-A1 DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS 4SC AG (DE) 2004-03-10 EP disclosed
US-20020165236-A1 Compounds for the treatment of protozoal diseases 4SC AG (DE) 2002-11-07 US disclosed
WO-2002070467-A1 DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS 4SC AG (DE) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165236-A1 Compounds for the treatment of protozoal diseases PKD2, PPOX, PKD1 F2 2898/4885TMPRSS6 502/4885CYP2D6 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.